[go: up one dir, main page]

ES2418459B1 - Relacionando agregación proteica con supervivencia de levadura - Google Patents

Relacionando agregación proteica con supervivencia de levadura Download PDF

Info

Publication number
ES2418459B1
ES2418459B1 ES201190025A ES201190025A ES2418459B1 ES 2418459 B1 ES2418459 B1 ES 2418459B1 ES 201190025 A ES201190025 A ES 201190025A ES 201190025 A ES201190025 A ES 201190025A ES 2418459 B1 ES2418459 B1 ES 2418459B1
Authority
ES
Spain
Prior art keywords
aggregation
enzyme
protein
cell
survey
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201190025A
Other languages
English (en)
Other versions
ES2418459R1 (es
ES2418459A2 (es
Inventor
Salvador VENTURA ZAMORA
Francesc Xavier AVILÉS PUIGVERT
Montserrat MORELL FERNÁNDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat Autonoma de Barcelona UAB
Original Assignee
Universitat Autonoma de Barcelona UAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat Autonoma de Barcelona UAB filed Critical Universitat Autonoma de Barcelona UAB
Publication of ES2418459A2 publication Critical patent/ES2418459A2/es
Publication of ES2418459R1 publication Critical patent/ES2418459R1/es
Application granted granted Critical
Publication of ES2418459B1 publication Critical patent/ES2418459B1/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/9065—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on CH-NH groups of donors (1.5)
    • G01N2333/90655—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1) in general
    • G01N2333/90661—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1) in general with a definite EC number (1.5.1.-)
    • G01N2333/90666—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Relacionando agregación proteica con supervivencia de levadura.#La invención se refiere a métodos para la identificación de compuestos capaces de prevenir la agregación de polipéptidos propensos a la agregación basados en el uso de proteínas de fusión. Las proteínas de fusión comprenden la proteína de interés y una enzima que es capaz de metabolizar un agente tóxico para la célula. Si el compuesto candidato previene la agregación de la proteína de fusión, el enzima se mantiene soluble y en forma activa, evitando así el efecto tóxico en la célula e incrementando la viabilidad celular respecto a la de células no expuestas al compuesto candidato. La invención también proporciona diferentes polipéptidos que contienen un polipéptido con tendencia a agregar y una enzima, y describe la utilización de los mismos.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40


Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
    imagen6
ES201190025A 2008-10-09 2009-10-09 Relacionando agregación proteica con supervivencia de levadura Active ES2418459B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08017708 2008-10-09
PCT/EP2009/063213 WO2010040842A1 (en) 2008-10-09 2009-10-09 Linking protein aggregation and yeast survival

Publications (3)

Publication Number Publication Date
ES2418459A2 ES2418459A2 (es) 2013-08-13
ES2418459R1 ES2418459R1 (es) 2013-10-11
ES2418459B1 true ES2418459B1 (es) 2014-08-12

Family

ID=41478848

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201190025A Active ES2418459B1 (es) 2008-10-09 2009-10-09 Relacionando agregación proteica con supervivencia de levadura

Country Status (2)

Country Link
ES (1) ES2418459B1 (es)
WO (1) WO2010040842A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015521863A (ja) * 2012-07-13 2015-08-03 エル． ホルツマン，ジョーダン アルツハイマー病の治療のための治療薬剤をスクリーニングするための細胞モデルと動物モデル
CN103525858B (zh) * 2013-09-29 2015-12-09 深圳大学 高通量筛选抗亨廷顿疾病活性物质的植物细胞模型的建立方法及其应用
GB201414038D0 (en) * 2014-08-07 2014-09-24 Univ Sussex The Alzheimer's disease
CN113552102B (zh) * 2021-07-16 2022-05-17 上海交通大学 一种基于荧光相关光谱检测有机溶剂诱导蛋白聚集的药物筛选方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982146B1 (en) * 1999-08-30 2006-01-03 The United States Of America As Represented By The Department Of Health And Human Services High speed parallel molecular nucleic acid sequencing
US7045290B2 (en) * 2001-02-15 2006-05-16 The University Of Chicago Yeast screens for treatment of human disease
KR100506766B1 (ko) * 2001-11-20 2005-08-05 (주)에이티젠 환경 스트레스에 내성을 부여하는 신규한 펩타이드 및이를 포함하는 융합단백질
US20090317825A1 (en) * 2005-12-12 2009-12-24 Elan Pharma International Limited Assay for parkinson's disease therapeutics and enzymatically active parkin preparations useful therein
WO2007103788A2 (en) * 2006-03-02 2007-09-13 The Board Of Trustees Of The University Of Illinois Yeast reporter system based on fusion proteins of sup35p

Also Published As

Publication number Publication date
ES2418459R1 (es) 2013-10-11
WO2010040842A9 (en) 2010-06-03
WO2010040842A1 (en) 2010-04-15
ES2418459A2 (es) 2013-08-13

Similar Documents

Publication Publication Date Title
ES2491891T3 (es) Marcaje celular para técnicas de resonancia magnética nuclear
ES2527455T3 (es) Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes
ES2524723T3 (es) Fructosil peptidil oxidasa y un sensor para analizar una proteína glucosilada
ES2596880T3 (es) Composición para el análisis de glicoproteínas
AR128541A2 (es) Métodos para modificar el punto isoeléctrico de anticuerpos mediante la sustitución de aminoácidos en la región de determinación de la complementariedad (cdr)
ES2418459B1 (es) Relacionando agregación proteica con supervivencia de levadura
ES2487846T3 (es) Anticuerpos anti-hepcindina y métodos de uso
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
ES2629749T3 (es) Inmunidad tumoral
ES2484142T3 (es) Diagnóstico molecular y clasificación del melanoma maligno
AR056748A1 (es) Solucion de cloruro de sodio para reconstitucion o dilucion de farmaco
AR090822A1 (es) Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos
AR084538A2 (es) Un anticuerpo que se fija sobre la p-selectina, su uso, un metodo para su obtencion, una composicion farmaceutica que lo comprende, una molecula de acido nucleico, un vector, y una celula hospedante y un kit
CO6280567A2 (es) Establecimiento de un anticuerpo monoclonal para detector de proteinas pag en la circulacion
ECSP077246A (es) Formulaciones Estabilizadoras
BR112019019920A2 (pt) explante de macrotecido, métodos e usos para o mesmo
ATE458824T1 (de) Zellfreie in-vitro-transkription und translation von membranproteinen in gebundene planare lipidschichten
Chang et al. Cl− uptake mechanism in freshwater-adapted tilapia (Oreochromis mossambicus)
ES2620740T3 (es) Epítopos de células T CD4 de PAP promiscuos
ES2564186T3 (es) Uso para fines de cribado de activos anti-envejecimiento de formas solubles de la proteína del tipo desmogleína I
WO2006017751A3 (en) Methods for the detection of molecular interactions within cells
Pu et al. Proteomic analysis of engineered cartilage
WO2009140390A3 (en) Serum markers for type ii diabetes mellitus
Matilainen et al. Fluorescent tools for in vivo studies on the ubiquitin-proteasome system
Enenkel Using native gel electrophoresis and phosphofluoroimaging to analyze GFP-tagged proteasomes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2418459

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20140812